Epix Announces Revised Results of Phase IIa Alzheimer's Trial
Posted on: Thursday, 17 January 2008, 09:00 CST
Epix Pharmaceuticals has reported revised results from a Phase IIa clinical trial of PRX-03140, its novel 5-HT4 agonist in Alzheimer's disease.
The trial was designed to assess the effects of PRX-03140 following two weeks of treatment as monotherapy and separately in combination with donepezil in patients with mild Alzheimer's disease and the company announced initial findings on December 18, 2007.
As a result of errors made in the transcription of data and calculation of the Alzheimer's disease assessment scale cognitive subscale (ADAS-cog) score, an independent re-analysis of the data has been conducted. The corrected results show that patients receiving 150mg of PRX-03140 orally once daily as monotherapy achieved a mean 3.6 point improvement on the ADAS-cog versus a 0.9 point worsening in patients on placebo, which continues to be statistically significant (p= 0.021). Data for the patients on a 50mg dose of PRX-03140 showed a one point improvement on the ADAS-cog. The monotherapy dose response (150mg versus 50mg versus placebo) continues to be statistically significant with p=0.026. There were no substantive changes in the results from the combination arms of the study.
In the Phase IIa clinical trial, PRX-03140 appeared to be well tolerated, both alone and in combination with donepezil (Aricept). No serious drug-related adverse events occurred during the trial. The two-week study also utilized other cognitive tests including Mindstreams, an automated battery of computerized cognitive function tests. Patients on monotherapy demonstrated significant (p<0.04) improvements in memory and visual-spatial indices as measured using Mindstreams when compared with placebo.
Michael Kauffman, CEO of Epix, said: "With our partner, GlaxoSmithKline, we are continuing with our plans to initiate a Phase IIb clinical trial program in Alzheimer's patients in the first half of 2008."
Source: Datamonitor
Related Articles
- TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial With Oral TRC102, An Inhibitor of Chemotherapy Resistance, in Combination With Alimta
- NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
- Clinical Trial Shows Ubiquinol Has Significant Effect on Patients With Congestive Heart Failure
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- Ortec Completes Patient Enrollment for Confirmatory Trial Evaluating OrCel(R) in Healing Venous Leg Ulcers
- MedImmune Begins Dosing of Lupus Patients in Phase 1 Clinical Trial
- Ecopia Begins Patient Dosing in Cancer Trial
- AmpliMed Begins Patient Enrollment for Phase I Trial of Amplimexon(TM) Plus Docetaxel in Patients With Lung, Breast and Prostate Cancer
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds